[1]ÕÅÑÇ´£.½áÍâ×ÔȻɱÉË/Tϸ°ûÁÜ°ÍÁöµÄÖÎÁÆÑо¿½øÕ¹[J].ÐÂÏçҽѧԺѧ±¨,2024,(4):397-400.[doi:10.7683/xxyxyxb.2024.04.019]
¡¡ZHANG Yachu.Research progress in the treatment of extranodal natural killer/T-cell lymphoma[J].Journal of Xinxiang Medical University,2024,(4):397-400.[doi:10.7683/xxyxyxb.2024.04.019]

µã»÷¸´ÖÆ

½áÍâ×ÔȻɱÉË/Tϸ°ûÁÜ°ÍÁöµÄÖÎÁÆÑо¿½øÕ¹

·ÖÏíµ½£º

²Î¿¼ÎÄÏ×/References:

£Û1£Ý¡¡TSE E,ZHAO W L,XIONG J,et al.How we treat NK/T-cell lymphomas£ÛJ£Ý.J Hematol Oncol,2022,15(1):74.
£Û2£Ý¡¡RENEAU J C,SHINDIAPINA P,BRAUNSTEIN Z,et al.Extranodal natural killer/T-cell lymphomas:current approaches and future directions£ÛJ£Ý.J Clin Med,2022,11(10):2699.
£Û3£Ý¡¡TIAN J,HAO M,LIU Q,et al.Efficacy and safety of PD-1 inhibitor alone or combined with chemotherapy in patients with relapsed or refractory extranodal natural Killer/T cell lymphoma:a retrospective study£ÛJ£Ý.Hematol Oncol,2023,41(3):396-406.
£Û4£Ý¡¡HE X,GAO Y,LI Z,et al.Review on natural killer/T-cell lymphoma£ÛJ£Ý.Hematol Oncol,2023,41(2):221-229.
£Û5£Ý¡¡LIM S H,HONG J Y,LIM S T,et al.Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma:clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease£ÛJ£Ý.Ann Oncol,2017,28(9):2199-2205.
£Û6£Ý¡¡YHIM H Y,KIM J S,MUN Y C,et al.Clinical outcomes and prognostic factors of up-front autologous stem cell transplantation in patients with extranodal natural killer/T cell lymphoma£ÛJ£Ý.Biol Blood Marrow Transplant,2015,21(9):1597-1604.
£Û7£Ý¡¡WANG J,WEI L,YE J,et al.Autologous hematopoietic stem cell transplantation may improve long-term outcomes in patients with newly diagnosed extranodal natural killer/T-cell lymphoma,nasal type:a retrospective controlled study in a single center£ÛJ£Ý.Int J Hematol,2018,107(1):98-104.
£Û8£Ý¡¡SONG G Y,YOON D H,SUH C,et al.Open-label,single arm,multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma£ÛJ£Ý.Bone Marrow Transplant,2021,56(5):1205-1208.
£Û9£Ý¡¡ALLEN P B,LECHOWICZ M J.Management of NK/T-cell lymphoma,nasal type£ÛJ£Ý.J Oncol Pract,2019,15(10):513-520.
£Û10£Ý¡¡KHARFAN-DABAJA M A,KUMAR A,AYALA E,et al.Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK/T cell lymphomas:an international collaborative effort on behalf of the guidelines committee of the American society for blood and marrow transplantation£ÛJ£Ý.Biol Blood Marrow Transplant,2017,23(11):1826-1838.
£Û11£Ý¡¡BRAMMER J E,CHIHARA D,POON L M,et al.Management of advanced and relapsed/refractory extranodal natural killer T-cell lymphoma:an analysis of stem cell transplantation and chemotherapy outcomes£ÛJ£Ý.Clin Lymphoma Myeloma Leuk,2018,18(1):e41-e50.
£Û12£Ý¡¡JEONG S H,SONG H N,PARK J S,et al.Allogeneic stem cell transplantation for patients with natural killer/T cell lymphoid malignancy:a multicenter analysis comparing upfront and salvage transplantation£ÛJ£Ý.Biol Blood Marrow Transplant,2018,24(12):2471-2478.
£Û13£Ý¡¡KANATE A S,DIGILIO A,AHN K W,et al.Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma,nasal type:a CIBMTR analysis£ÛJ£Ý.Br J Haematol,2018,182(6):916-920.
£Û14£Ý¡¡AWASTHI P,DWIVEDI M,KUMAR D,et al.Insights into intricacies of the latent membrane protein-1 (LMP-1) in EBV-associated cancers£ÛJ£Ý.Life Sci,2023,313:121261.
£Û15£Ý¡¡LIU J Y,ZHANG J M,ZHAN H S,et al.EBV-specific cytotoxic T lymphocytes for refractory EBV-associated post-transplant lymphoproliferative disorder in solid organ transplant recipients:a systematic review£ÛJ£Ý.Transpl Int,2021,34(12):2483-2493.
£Û16£Ý¡¡KIM W S,OKI Y,KIM S J,et al.Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma:results of a multicenter study£ÛJ£Ý.Ann Hematol,2021,100(10):2529-2539.
£Û17£Ý¡¡BOLLARD C M,GOTTSCHALK S,LEEN A M,et al.Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer£ÛJ£Ý.Blood,2007,110(8):2838-2845.
£Û18£Ý¡¡KIM S J,RYU K J,PARK B,et al.Exosomal and soluble programed death-ligand 1 (PD-L1) predicts responses to pembrolizumab in patients with extranodal NK/T-cell lymphoma£ÛJ£Ý.Cancers,2022,14(22):5618.
£Û19£Ý¡¡TSE E,KWONG Y L.Recent advances in the diagnosis and treatment of natural killer cell malignancies£ÛJ£Ý.Cancers (Basel),2022,14(3):597.
£Û20£Ý¡¡SONG T L,NAIRISM¦FGI M L,LAURENSIA Y,et al.Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma£ÛJ£Ý.Blood,2018,132(11):1146-1158.
£Û21£Ý¡¡KWONG Y L,CHAN T S Y,TAN D,et al.PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing L-asparaginase£ÛJ£Ý.Blood,2017,129(17):2437-2442.
£Û22£Ý¡¡LI X,CHENG Y,ZHANG M,et al.Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma£ÛJ£Ý.J Hematol Oncol,2018,11(1):15.
£Û23£Ý¡¡KIM S J,HYEON J,CHO I,et al.Comparison of efficacy of pembrolizumab between epstein-barr virus positive and negative relapsed or refractory non-hodgkin lymphomas£ÛJ£Ý.Cancer Res Treat,2019,51(2):611-622.
£Û24£Ý¡¡CHAN T S Y,LI J,LOONG F,et al.PD1 blockade with low-dose nivolumab in NK/T cell lymphoma failing L-asparaginase:efficacy and safety£ÛJ£Ý.Ann Hematol,2018,97(1):193-196.
£Û25£Ý¡¡TAO R,FAN L,SONG Y,et al.Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma:a multicenter,single-arm,phase 2 trial (ORIENT-4)£ÛJ£Ý.Signal Transduct Target Ther,2021,6(1):365.
£Û26£Ý¡¡CAI J,LIU P,HUANG H,et al.Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma£ÛJ£Ý.Signal Transduct Target Ther,2020,5(1):289.
£Û27£Ý¡¡KIM S J,LIM J Q,LAURENSIA Y,et al.Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma:an open-label phase 2 study£ÛJ£Ý.Blood,2020,136(24):2754-2763.
£Û28£Ý¡¡WANG L,WANG H,LI P F,et al.CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal NK/T cell lymphoma,nasal type£ÛJ£Ý.Ann Hematol,2015,94(8):1381-1388.
£Û29£Ý¡¡HARI P,RAJ R V,OLTEANU H.Targeting CD38 in refractory extranodal natural killer cell-T-cell lymphoma£ÛJ£Ý.N Engl J Med,2016,375(15):1501-1502.
£Û30£Ý¡¡AEPPLI S,DRIESSEN C,GRAF L,et al.Systemic treatment of a patient with relapsed and refractory extranodal NK/T-cell lymphoma (ENKL) and meningeosis leukemica with daratumumab£ÛJ£Ý.Hematol Oncol,2018,36(4):713-714.
£Û31£Ý¡¡HUANG H,ZHU J,YAO M,et al.Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma,nasal type:an open-label,single-arm,multicenter,phase 2 study£ÛJ£Ý.J Hematol Oncol,2021,14(1):25.
£Û32£Ý¡¡JEONG S H.Extranodal NK/T cell lymphoma£ÛJ£Ý.Blood Res,2020,55(s1):S63-S71.
£Û33£Ý¡¡FENG Y,RAO H,LEI Y,et al.CD30 expression in extranodal natural killer/T-cell lymphoma,nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China£ÛJ£Ý.Chin J Cancer,2017,36(1):43.
£Û34£Ý¡¡KIM H K,MOON S M,MOON J H,et al.Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin£ÛJ£Ý.Blood Res,2015,50(4):254-256.
£Û35£Ý¡¡POON L M,KWONG Y L.Complete remission of refractory disseminated NK/T cell lymphoma with brentuximab vedotin and bendamustine£ÛJ£Ý.Ann Hematol,2016,95(5):847-849.
£Û36£Ý¡¡KIM S J,YOON D H,KIM J S,et al.Efficacy of brentuximab vedotin in relapsed or refractory high-CD30-expressing non-hodgkin lymphomas:results of a multicenter,open-labeled phase II trial£ÛJ£Ý.Cancer Res Treat,2020,52(2):374-387.
£Û37£Ý¡¡CHAN T S,TSE E,KWONG Y L.Chidamide in the treatment of peripheral T-cell lymphoma£ÛJ£Ý.Onco Targets Ther,2017,10:347-352.
£Û38£Ý¡¡SHI Y,DONG M,HONG X,et al.Results from a multicenter,open-label,pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma£ÛJ£Ý.Ann Oncol,2015,26(8):1766-1771.
£Û39£Ý¡¡SHI Y,JIA B,XU W,et al.Chidamide in relapsed or refractory peripheral T cell lymphoma:a multicenter real-world study in China£ÛJ£Ý.J Hematol Oncol,2017,10(1):69.
£Û40£Ý¡¡GAO Y,HUANG H,WANG X,et al.Anti-PD-1 antibody (sintilimab) plus histone deacetylase inhibitor (chidamide) for the treatment of refractory or relapsed extranodal natural killer/T cell lymphoma,nasal type (r/r-ENKTL):preliminary results from a prospective,multicenter,single-arm,phase ¢ñb/¢ò trial (SCENT)£ÛJ£Ý.Blood,2020,136(Suppl 1):39-40.
£Û41£Ý¡¡FENG Y,ZHONG M,LIU Y,et al.Expression of TIM-3 and LAG-3 in extranodal NK/T cell lymphoma,nasal type£ÛJ£Ý.Histol Histopathol,2018,33(3):307-315.
£Û42£Ý¡¡FLINN I W,O¡äBRIEN S,KAHL B,et al.Duvelisib,a novel oral dual inhibitor of PI3K-¦Ä,¦Ã,is clinically active in advanced hematologic malignancies£ÛJ£Ý.Blood,2018,131(8):877-887.
£Û43£Ý¡¡MEL S D,HUE S S,JEYASEKHARAN A D,et al.Molecular pathogenic pathways in extranodal NK/T cell lymphoma£ÛJ£Ý.J Hematol Oncol,2019,12(1):33.